Designed for adaptability and integration

Our next-generation platform is based on native Outer Membrane Vesicles (nOMVs) derived from Neisseria meningitidis that provide intrinsic innate immune activation. The platform supports flexible multivalent and broad-spectrum vaccine design: multiple (conserved) antigens can be displayed on the nOMVs and/or co-administered with them as an adjuvant, enabling tailored broad immune response strategies across multiple routes of administration. This design allows vaccine approaches to be adapted to different transmission dynamics and public-health needs, while maintaining a consistent underlying technology.

Rather than focusing on a single indication, the AdJane platform incorporates foundational capabilities that can be applied, adapted and integrated across different vaccine strategies and development contexts. This approach supports continuity across programs while allowing components to be adjusted independently as requirements evolve.

The platform can be applied across:

  • Viral and bacterial pathogens
  • Mono-, multivalent and broad-spectrum vaccine concepts
  • Mucosal and intramuscular routes of administration
  • Unknown and emerging threats

Evaluation and application

The platform has been independently evaluated by multiple leading international initiatives. These applications demonstrate the platform’s suitability for reuse across diverse infectious disease scenarios.

Stability and scalability

Our platform has demonstrated long-term stability under standard refrigerated conditions (2–8 °C).

This stability supports:

  • long-term stockpiling;
  • simplified global distribution;
  • deployment in both pandemic response and routine immunization settings.


The platform is supported by a robust and reproducible OMV manufacturing process, designed for scalability, batch-to-batch consistency and integration into existing vaccine manufacturing infrastructures.

Intellectual property and partnerships

Our platform has been extensively developed and validated and has been described by multiple peer-reviewed publications. AdJane has consolidated this foundation into its fully owned platform and patent portfolio. This provides us with the freedom to operate to develop vaccines across multiple disease areas and allows selective partnering without restrictions or encumbrances. Our platform IP also includes patents covering modulation of innate immune activation, supporting flexibility across both prophylactic and therapeutic vaccine concepts.